Seeking Surrogate Markers for Diabetic Macular Edema.
暂无分享，去创建一个
[1] Jennifer K. Sun,et al. Association Between Change in Visual Acuity and Change in Central Subfield Thickness During Treatment of Diabetic Macular Edema in Participants Randomized to Aflibercept, Bevacizumab, or Ranibizumab: A Post Hoc Analysis of the Protocol T Randomized Clinical Trial. , 2019, JAMA ophthalmology.
[2] G. Ying,et al. Macular Morphology and Visual Acuity in Year Five of the Comparison of Age-related Macular Degeneration Treatments Trials. , 2019, Ophthalmology.
[3] P. Mitchell,et al. Effect of Ranibizumab on the Decision to Drive and Vision Function Relevant to Driving in Patients With Diabetic Macular Edema: Report From RESTORE, RIDE, and RISE Trials. , 2016, JAMA ophthalmology.
[4] N. Bressler,et al. Vision-related function after ranibizumab treatment for diabetic macular edema: results from RIDE and RISE. , 2014, Ophthalmology.
[5] Jennifer K. Sun,et al. Disorganization of the retinal inner layers as a predictor of visual acuity in eyes with center-involved diabetic macular edema. , 2014, JAMA ophthalmology.
[6] N. Bressler,et al. Use of patient-reported outcomes in medical product development: a report from the 2009 NEI/FDA Clinical Trial Endpoints Symposium. , 2010, Investigative ophthalmology & visual science.
[7] F. Ferris,et al. Report from the NEI/FDA Ophthalmic Clinical Trial Design and Endpoints Symposium. , 2008, Investigative ophthalmology & visual science.